Newly-launched ULB oncology spinout Epics Therapeutics will aim to develop drugs targeting malignant epigenetic RNA modifications.

Epics Therapeutics, a Belgium-based oncology spinout of Université libre de Bruxelles (ULB), officially launched today with €7.2m ($8.2m) in funding from investors including ULB’s university venture fund Theodorus.
The round was led by Alain Parthoens of Newton Biocapital and included regional investment firms InvestSud and Regional Investment Company of Wallonia.
VC fund Sambrinvest also supplied Epics with funding, as did private investor Pierre Drion, chairman of the university’s nonprofit arm Fondation ULB, and angel investor Jean Combalbert.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?